ERBB2 and breast cancer: The use of trastuzumab combined with chemotherapy in neoadjuvant therapy of HER2-positive patients has a higher pCR rate than that of chemotherapy alone, which lays the cornerstone position for trastuzumab in neoadjuvant therapy of HER2-positive breast cancer patients [10].